RepliCel Reports Progress on Shiseido Technology

Collapse
X
 
  • Time
  • Show
Clear All
new posts

  • Artista
    replied
    I had spoken with Tammey George of Replicel last night (US time)
    We have had a few talks in the past so it was great to speak with her again.
    It was a very nice conversation- basically what we have been reading online here.
    This is very positive advancement of theirs and not just with hair.

    Leave a comment:


  • Artha
    replied
    Originally posted by hellouser
    They're supposed to be starting Phase II this year which should take them about 3 years to complete. If and when completed, they should have something on the market in Asia for us to use soon after. 3 years isn't that bad of a time frame. Of course, Histogen *should* be out before then too.
    And Follica that juste finished their second trial.

    Plus the Taiwan trial that supose to finish in 2016

    Leave a comment:


  • joachim
    replied
    Originally posted by hellouser
    They're supposed to be starting Phase II this year which should take them about 3 years to complete. If and when completed, they should have something on the market in Asia for us to use soon after. 3 years isn't that bad of a time frame. Of course, Histogen *should* be out before then too.
    3 years, really?

    damn it. this is so faaaar away.

    Leave a comment:


  • joachim
    replied
    Originally posted by hellouser
    Good news;

    RepliCel Life Sciences’ Licensing Partner, Shiseido, Opens Cell Processing and Expansion Facility in Japan to Advance RCH-01, a Treatment for Pattern Baldness

    Source:

    http://www.replicel.com/replicel-lif...tern-baldness/
    great. going into fully automated cell production hopefully

    Leave a comment:


  • Artha
    replied
    RepliCel Life Sciences Inc. Announces Closing of Second Tranche of Private Placement

    VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 21, 2014)


    Leave a comment:


  • hellouser
    replied
    Originally posted by yagazooci
    They ARE the science of Replicel, and previously Trichoscience. It was their findings that caused them to seek business-minded folks and form the company. They have a very good team now it seems. They differed from Aderans in the specific cell they used. DSCC ( Dermal Sheath Cup Cells) as opposed to dermal papilla cells. They think that is the difference maker. They have vastly improved their cell multiplication time frame, their injection paraphernalia, (more precise amounts/depths)their culture in the multiplication process etc. These things will all lead them to greater success and a shot at viability. They tout this same technology as potentially effective in a host of cell deficiency applications. Surely they aren't willy nilly on it all. They have way too much credibility to be rolling the dice… going to be interesting.
    They're supposed to be starting Phase II this year which should take them about 3 years to complete. If and when completed, they should have something on the market in Asia for us to use soon after. 3 years isn't that bad of a time frame. Of course, Histogen *should* be out before then too.

    Leave a comment:


  • yagazooci
    replied
    They ARE the science of Replicel, and previously Trichoscience. It was their findings that caused them to seek business-minded folks and form the company. They have a very good team now it seems. They differed from Aderans in the specific cell they used. DSCC ( Dermal Sheath Cup Cells) as opposed to dermal papilla cells. They think that is the difference maker. They have vastly improved their cell multiplication time frame, their injection paraphernalia, (more precise amounts/depths)their culture in the multiplication process etc. These things will all lead them to greater success and a shot at viability. They tout this same technology as potentially effective in a host of cell deficiency applications. Surely they aren't willy nilly on it all. They have way too much credibility to be rolling the dice… going to be interesting.

    Leave a comment:


  • hellouser
    replied
    Here's some more info;

    Some time before 2003 Dr. Rolf Hoffman & Dr. Kevin McElwee published a study on Dermal Sheath Cup Cells inducing hair follicles;

    Green fluorescent protein (GFP)-expressing wild-type, and nontransgenic mouse vibrissa follicle cells were cultured and implanted to mouse ears and footpads. Dermal papiller (DP)-derived cells and cells from the peribulbar dermal sheath "cup" (DSC) induced new hair follicles in both implanted ears a …


    Shortly after that, the method was patented by Dr. Rolf Hoffman & Dr. Kevin McElwee.

    The present invention relates to a method for isolating hair follicle mesenchymal stem cells and to the use thereof for therapy and prophylaxis as well as for cosmetic treatments.


    The good news?

    Both these guys are working at Replicel now;



    Hoffman's bio:

    Leave a comment:


  • hellouser
    replied
    Originally posted by yagazooci
    They have the territorial license and rights from Replicel to service the Asean countries with Replicel's patented technology, which is about 2.1 billion people, once the efficacy is proven up. Cant help but think that a hallmark long-lived company like Sheseido like what they see. Its right in their wheelhouse too. They are doing parallel trials with replicel and trading knowledge gleaned along the way. Seems like replicel wants to do this right. Being sent back to the drawing board is not an option. They have power in their corner with Sheseido Id say… more than they'd had all along. thats what I think. Bully for us!
    What's also interesting is how Desmond mentioned that many research teams overcame culturing of DP cells and retaining their properties a LONG time ago and we, the hair loss community/baldites have been clueless about their findings. I would think its not really a stretch to assume that Replicel had overcome these obstacles themselves as well. I do remember there was some kind of change in their protocol, which perhaps means 3D culturing instead of 2D culturing?? If that's the case, then we might be in for a surprise with results.

    Leave a comment:


  • yagazooci
    replied
    They have the territorial license and rights from Replicel to service the Asean countries with Replicel's patented technology, which is about 2.1 billion people, once the efficacy is proven up. Cant help but think that a hallmark long-lived company like Sheseido like what they see. Its right in their wheelhouse too. They are doing parallel trials with replicel and trading knowledge gleaned along the way. Seems like replicel wants to do this right. Being sent back to the drawing board is not an option. They have power in their corner with Sheseido Id say… more than they'd had all along. thats what I think. Bully for us!

    Leave a comment:


  • hellouser
    replied
    Originally posted by yagazooci
    Research of this type is sloooow. Japanese governance seems to have realized that tho finding such products to be safe and effective takes time, they can cut the bureaucracy on their end and lead the way in being first out the gate in such technologies. I read somewhere that this jibes with their economic reform. And with other streams proffered by folks like Replicel in tendon and skin aging repair, there seems to be something of a boon in the industry coming… Bully for these biotech industry leaders I say.
    Their economy is going to see a HUGE boost if they push these treatments out of the door quickly. I would not only go to Japan to get a socially tolerable head of hair, but I'd take a few more days off and go tour around Japan and dump even more money on hotels, travels, food, night life, etc. I'll do the very same anywhere and I'm sure many others would take advantage of the opportunity.

    The hair loss industry is in the billions already with shit products over the counter. Imagine what it'd do if working treatments were isolated to a single country?

    Leave a comment:


  • yagazooci
    replied
    Research of this type is sloooow. Japanese governance seems to have realized that tho finding such products to be safe and effective takes time, they can cut the bureaucracy on their end and lead the way in being first out the gate in such technologies. I read somewhere that this jibes with their economic reform. And with other streams proffered by folks like Replicel in tendon and skin aging repair, there seems to be something of a boon in the industry coming… Bully for these biotech industry leaders I say.

    Leave a comment:


  • hellouser
    replied
    Originally posted by downandout
    Hellouser, possibly the best line of the whole article "Legislative support has come from the introduction of new laws to expedite otherwise lengthy clinical research and trial application processes to promote competitive advantage in the international market"
    NICE! I think I'm going to email Tammy from Replicel and see if that part means what we hope it does.

    I've said it before in other threads that the clinical trials in other jurisdictions use an arbitrary number for years to prove efficacy, in essence, what does 15 years of trials tell us that 5 years does not?

    Leave a comment:


  • FearTheLoss
    replied
    is this phase 2b for them or phase 3?

    Leave a comment:


  • downandout
    replied
    Hellouser, possibly the best line of the whole article "Legislative support has come from the introduction of new laws to expedite otherwise lengthy clinical research and trial application processes to promote competitive advantage in the international market"

    Leave a comment:

Working...